(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 June 2013 (20.06.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/090921 A1

(51) International Patent Classification:
C07D 311/00 (2006.01)

(21) International Application Number:
PCT/US2012/070168

(22) International Filing Date:
17 December 2012 (17.12.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/576,890 16 December 2011 (16.12.2011) US

(71) Applicant: **OLEMA PHARMACEUTICALS, INC.** [US/US]; 665 3rd Street, Suite 250, San Francisco, CA 94107 (US).

(72) Inventors: **KUSHNER, Peter, J.**; 1362 6th Avenue, San Francisco, CA 94122 (US). **MYLES, David, C.**; 1665 Thousand Oaks Boulevard, Berkeley, CA 94707 (US). **HARMON, Cyrus, L.**; 19 Brighton Avenue, Bolinas, CA 94924 (US). **GALLAGHER, Leslie, Carol Hodges**; 2101 Shoreline Drive, #413, Alameda, CA 94501 (US).

(74) Agent: **BELLOWS, Brent, R.**; KNOWLES INTELLECTUAL PROPERTY STRATEGIES, LLC, 400 Perimeter Center Terrace Ne, Suite 125, Atlanta, GA 30346 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF




FIG. 3

(57) Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP- 1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-l-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methyl-pyrrolidin- 1 -yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.

WO 2013/090921 A1

Published:

— *with international search report (Art. 21(3))*